(Q35674384)

9 August 2017

1 reference

title

Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? (English)

1 reference

9 August 2017

1 reference

1 reference

Peter C Waldmeier

1

1 reference

9 August 2017

William G Tatton

series ordinal

2

1 reference

9 August 2017

publication date

1 March 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

9

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

210-218

1 reference

Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neurotrophins and Neurodegenerative Diseases: Receptors Stuck in Traffic?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Apoptosis in neurodegenerative diseases: the role of mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Glutathione, oxidative stress and neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Hypoxia signaling to genes: significance in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Axonal transport of neurofilaments in normal and disease states

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neuroinflammatory processes in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Beta-propellers: associated functions and their role in human diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Parkinson's disease. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Advances in the pharmacological management of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Clinical trials in neuroprotection. 23-25 January 2003, Key Biscayne, Florida, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Therapeutic developments in the treatment of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

1 reference

7 January 2021

Coenzyme Q10 in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Apoptosis in Parkinson's disease: signals for neuronal degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Prospects for antiapoptotic drug therapy of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Caspase pathways, neuronal apoptosis, and CNS injury

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neuronal death in brain infarcts in man

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Changes in caspase expression in Alzheimer's disease: comparison with development and aging

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Dissociation between neurodegeneration and caspase-11-mediated activation of caspase-1 and caspase-3 in a mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The JNK/c-Jun cascade and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

FADD: A link between TNF family receptors and caspases in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Estradiol enhances Akt activation in cortical explant cultures following neuronal injury

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Controlling apoptosis by inhibition of caspases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Minocycline enhances MPTP toxicity to dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

p53: good cop/bad cop.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Role of alpha-2 agonists in neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Ovarian steroids reduce apoptosis induced by trophic insufficiency in nerve growth factor-differentiated PC12 cells and axotomized rat facial motoneurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Slowing Parkinson's disease progression: recent dopamine agonist trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Clinical biomarkers in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Apoptotic cell death: its implications for imaging in the next millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Imaging and neurochemical markers for diagnosis and disease progression in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Imaging end points for monitoring neuroprotection in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Cell death and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Early diagnosis of Alzheimer's disease: clinical and economic benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

Pathology and pathways of Alzheimer's disease with an update on new developments in treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2903000-9

7 January 2021

10.1016/S1359-6446(03)03000-9

Identifiers

DOI

1 reference

9 August 2017

1 reference